← Back to news
Regulatory

FDA Tightens Compounding Rules as Tirzepatide Shortage Is Officially Resolved

#FDA#tirzepatide#compounding#GLP-1#Mounjaro#503B#shortage

The U.S. Food and Drug Administration has officially declared the national shortage of tirzepatide injection resolved and issued new guidance that sharply limits compounding pharmacies' ability to produce copies of the blockbuster GLP-1 medication. The move affects millions of patients who turned to compounded versions during the prolonged supply crunch, and it marks the FDA's clearest signal yet that the era of large-scale GLP-1 compounding is ending.

Tirzepatide, a dual GIP/GLP-1 receptor agonist marketed by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management), had been on the FDA's Drug Shortage List since 2023. That listing was the legal linchpin that allowed Section 503B outsourcing facilities to produce compounded versions at scale — often at a fraction of the branded price.

What the New Guidance Says

The FDA's updated policy, published in conjunction with a Reuters report on April 1, includes several key provisions:

  • Shortage status removed: Tirzepatide injection is no longer listed as in shortage, eliminating the primary legal basis for 503B bulk compounding.
  • Transition period: Compounders have a limited grace window to wind down production without facing immediate enforcement, though the FDA has not specified the exact end date.
  • 503A pharmacies: Traditional compounding pharmacies operating under Section 503A may still fill patient-specific prescriptions where a clinical need exists, but cannot produce large batches.
  • Ongoing monitoring: The FDA noted that while supply logistics remain uneven in some regions, the overall national supply is adequate.

Why This Matters

The compounded GLP-1 market exploded during the shortage years, with some estimates putting it at several billion dollars annually. For patients, compounded versions cost as little as $200–$400 per month compared to $1,000+ for branded products — making them the only affordable option for many.

The FDA's position is that now that Lilly can meet demand, patient safety requires returning to the standard regulatory framework. Compounded drugs do not undergo the same manufacturing oversight, stability testing, or sterility validation as FDA-approved products.

Industry observers expect legal challenges from compounding pharmacy trade groups, echoing the lawsuits filed when semaglutide compounding was similarly restricted in late 2024.

What Patients Should Do Now

Healthcare providers are advising patients on compounded tirzepatide to begin planning their transition. Options include switching to branded Mounjaro or Zepbound, exploring manufacturer savings programs, or discussing alternative GLP-1 therapies with their prescriber — including the newly approved oral option Foundayo (orforglipron).